The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Pegloticase & Methotrexate Combination Therapy May Benefit Patients with Uncontrolled Gout

Pegloticase & Methotrexate Combination Therapy May Benefit Patients with Uncontrolled Gout

December 11, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ATLANTA—Based on data from a randomized clinical trial, 42% of patients with uncontrolled gout treated with pegloticase still have a therapeutic response after six months of therapy. Additionally, low to moderate levels of methotrexate or azathioprine attenuate the development of anti-drug antibodies, allowing patients to remain on therapy longer and attain a more complete therapeutic effect.

You Might Also Like
  • Pharmacokinetics May Be Factor in Success of Pegloticase Therapy for Gout
  • RA Patients May Safely Stop Methotrexate in Tofacitinib Combination Therapy
  • Certolizumab Pegol Combination Therapy Better than Methotrexate Monotherapy in DMARD-Naive Patients with RA
Explore This Issue
February 2020, January 2020
Also By This Author
  • FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare

This study, presented during the 2019 ACR/ARP Annual Meeting in November, evaluated pegloticasetreated patients with uncontrolled gout in a retrospective chart review from a community rheumatology practice. The goal was to determine if immunomodulator treatment would lower the risk of anti-drug antibodies and provide a more complete treatment response for patients. Patients receiving subcutaneous or oral methotrexate were also included in the review.1 

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers extracted data on patient responses, which included the duration of pegloticase therapy, gout flares, infusion reactions and methotrexate dosing. Other data included uric acid levels, liver function tests, renal function, hemoglobin and white blood cell counts. Patients’ complete blood count and comprehensive metabolic panel parameters were also closely monitored.

The Results
Ten patients fit the study’s inclusion criteria, nine of whom were men with an average age of 52.3 years and visible tophi.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Methotrexate exposure varied, with 10 patients having received methotrexate and only one patient receiving oral methotrexate. Nine of these patients received methotrexate prior to pegloticase treatment.

At the time of data collection, five patients were complete responders, having received approximately 16 pegloticase doses for about 32 weeks. Three patients were still responding while actively receiving pegloticase, having received 10, five and two doses, respectively. One patient stopped therapy due to a loss of response and a mild infusion reaction, and another patient stopped due to a methotrexate injection-related issue. One patient required prednisone for gout flare.

Liver function test and complete blood count parameters were stable throughout therapy, except in one patient. This patient had a mild, transient alcohol-related liver function test elevation and pancytopenia that improved after treatment and stopping methotrexate use. This patient remained on pegloticase and continued on as a responder.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

This small, retrospective study showed that methotrexate, when combined with pegloticase, appears to alleviate the formation of clinically significant anti-drug antibodies. The combination enables more difficult-to-treat gout patients to receive a more complete duration of pegloticase therapy.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: Gout Resource CenterIssue: February 2020, January 2020

You Might Also Like:
  • Pharmacokinetics May Be Factor in Success of Pegloticase Therapy for Gout
  • RA Patients May Safely Stop Methotrexate in Tofacitinib Combination Therapy
  • Certolizumab Pegol Combination Therapy Better than Methotrexate Monotherapy in DMARD-Naive Patients with RA
  • FDA Approves Duzallo for Hyperuricemia in Patients with Uncontrolled Gout

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)